The dual SRC-ABL inhibitors in Ph+ acute lymphoblastic leukemia to enhance synergy between targeted BCR-ABL and BCL-2 inhibitors

Authors :: Bill H. Chang
Brian J. Druker
Jeffrey W. Tyner
Jessica Leonard
Stephen E. Spurgeon
Marc M. Loriaux
Brandon Hayes-Lattin
Elie Traer
Source :: Journal of Clinical Oncology. 33:7073-7073
Publication Year :: 2015
Publisher :: American Society of Clinical Oncology (ASCO), 2015.
Abstract: 7073 Background: Outcomes in adult Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL) remain poor with a 5 year overall survival of less than 40%. Addition of the targeted BCR-A...

Subjects :: Cancer Research
ABL
Philadelphia Chromosome Positive
Oncology
business.industry
hemic and lymphatic diseases
Lymphoblastic Leukemia
Cancer research
Overall survival
Medicine
business
Proto-oncogene tyrosine-protein kinase Src
Ph+ acute lymphoblastic leukemia

Full Text Access

Tools